Version Française
OK
Logo retour accueil

Last news

  • 2012 Annual Results

    Evry, Monday, April 15, 2013 – IntegraGen,  today announced its financial results for the fiscal year ending December 31, 2102. The accounts were examined during the meeting of the Board of Directors held on April 11, 2013.

    Read more

  • Lab21 and IntegraGen : agreement for a CE marked assay

    Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic

    Read more

Home

IntegraGen’s vocation is firstly to establish the link between innovations derived from molecular research and medical practise, by developing biomarkers for autism and oncology specifically intended for clinical use, and subsequently to make its genomics services available to practitioners and researchers thanks to its exceptional technological and scientific know-how.

With the support of its network of partners and experts, IntegraGen is now well established as one of the leaders in its sector.

Autism Oncology Services
Disclaimers - Mentions légales - Crédits